Table 1 Patient characteristics.

From: Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Characteristic

Total patients (%)

N = 157

Age

 Median (range), years

66 (61–75)

  < 65 years

67 (42.7%)

  > 65 years

90 (57.5%)

Sex

 Female

96 (61.1%)

 Male

61 (38.9%)

Brain metastasis

68 (43.3%)

Stage

 3B

8 (5.1%)

 4A

40 (25.5%)

 4B

109 (69.4)

Tumor size

 < 3 cm

32 (20.4%)

 ≥ 3 cm

125 (79.6%)

Nodal stage

 N0-2

48 (30.6%)

 N3

109 (69.4%)

Performance status

 ECOG 0–1

138 (87.9%)

 ECOG ≥ 2

19 (12.1%)

EGFR mutation

 Exon 19 deletion

74 (47.1%)

 Exon 21 L858R substitution

74 (47.1%)

 Uncommon mutation

6 (3.8%)

 Complex mutation

3 (2.0%)

EGFR-TKI

 Gefitinib

22 (14.0%)

 Erlotinib

67 (42.7%)

 Afatinib

68 (43.3%)

  1. EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
Back to article page